Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Joris Versteden"'
Autor:
Ri Liesner, Joris Versteden, Shannely Lowndes, Johannes Oldenburg, Larisa Belyanskaya, Anna Pavlova
Publikováno v:
Blood. 132:1204-1204
Background: The SIPPET study investigated inhibitor development in 251 previously untreated patients (PUPs) treated with either plasma-derived FVIII products containing von Willebrand factor (pdFVIII/VWF; n = 125), or recombinant FVIII (rFVIII; n = 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74654381833bb772937998034d6f76c2
https://doi.org/10.1182/blood-2018-99-110608
https://doi.org/10.1182/blood-2018-99-110608
Autor:
Robert Klamroth, Susan Halimeh, Larisa Belyanskaya, M. Jansen, Anna Pavlova, Joris Versteden, Johannes Oldenburg
Publikováno v:
Blood. 132:5034-5034
Introduction/Objective: The development of FVIII inhibitors remains the greatest challenge to the treatment of previously untreated patients (PUPs) with haemophilia A. Uncontrolled studies in PUPs have suggested that immunogenicity of FVIII concentra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79c06ef704713fcf66f50f1e097b552c
https://doi.org/10.1182/blood-2018-99-116577
https://doi.org/10.1182/blood-2018-99-116577
Autor:
Ji-Guang Wang, Joris Versteden, Kazuomi Kario, Paul-Egbert Reimitz, Prakash Deedwania, Josep Redon
Publikováno v:
Journal of the American Society of Hypertension. 9:e25
Meta-analysis of blood pressure (BP) reductions with olmesartan medoxomil (OM) compared with active control (AC) in patients (pts) with hypertension (HTN) Josep Redon,y, 6 Prakash Deedwania, Kazuomi Kario, Jiguang Wang, Joris Versteden, Paul-Egbert R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::540eadad1a0fe39d06e6f396d4cad108
https://doi.org/10.1016/j.jash.2015.03.060
https://doi.org/10.1016/j.jash.2015.03.060